Table 3.

Patient demographics, disease activity, and hydroxychloroquine (HCQ) medication adherence (at baseline) for the standard of care (SOC) and cellular text messaging reminder (CTMR) groups.

VariableSOC, n = 22CTMR, n = 19Total No. Patients, n = 41
Mean (SD)N (% of total)Mean (SD)N (% of total)Mean (SD)N (% of total)
Age at the time of the study, yrs18.6 (2.6)18.7 (2.5)18.6 (2.5)
Weight, kg75 (18.2)71 (18.7)73 (18.4)
Medications
  HCQ, mg/day327 (93)324 (75)326 (84)
  HCQ, mg/kg/day4.6 (1.6)4.8 (1.2)4.7 (1.4)
  HCQ dose frequency
    Every other day1 (4)1 (5)2 (5)
    1 time a day18 (82)15 (79)23 (80)
    2 times a day3 (14)3 (16)6 (15)
  Prednisone, mg/day14 (17)15 (19)14 (17.5)
  Pulse methylprednisolone3 (16)3 (7)
  Nonsteroidal antiinflammatory drugs8 (36)10 (53)18 (44)
  Immunosuppressive medications*15 (68)14 (74)29 (71)
  Antihypertensive medications12 (55)8 (42)20 (49)
Disease activity indices
  Disease activity (SLEDAI)3.7 (4.0)7.9 (7.1)5.5 (5.9)
  Disease damage (SDI)0.8 (1.6)0.7 (1.7)0.8 (1.6)
  Physician global assessment of disease activity**1.9 (1.6)2.8 (2.3)2.3 (2.0)
  Patient well-being7.6 (2.0)7.2 (1.9)7.4 (1.9)
Medication adherence
  MASRI80 (21)83 (19)81 (20)
  Pharmacy refill data52 (32)64 (45)57 (33)
    No. patients with adherence > 80%6 (27)7 (37)13 (32)
  HCQ levels†† (p < 0.03)0.46 (0.55)0.64 (0.45)0.54 (0.51)
  • * E.g., mycophenolate mofetil, azathioprine. SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; 0 = inactive disease. SDI: Systemic Lupus International Collaboration Clinics Damage Index; 0 = no damage.

  • ** Visual analog scale 0 to 10; 0 = inactive disease; 10 = very active disease.

  • Visual analog scale 0 to 10; 0 = very poor; 10 = very well. MASRI: Medication Adherence Self-Report Inventory (0 to 100); 0 = no medication taken; 100 = all doses taken as prescribed.

  • †† Concentration measured in blood.